{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:50:53Z","timestamp":1793361053616,"version":"4.5.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tolinapant (ASTX660) is a potent, nonpeptidomimetic antagonist of cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1\/2) and X-linked IAP, which is currently being evaluated in a phase 2 study in T-cell lymphoma (TCL) patients. Tolinapant has demonstrated evidence of single-agent clinical activity in relapsed\/refractory peripheral TCL and cutaneous TCL. To investigate the mechanism of action underlying the single-agent activity observed in the clinic, we have used a comprehensive translational approach integrating in vitro and in vivo models of TCL confirmed by data from human tumor biopsies. Here, we show that tolinapant acts as an efficacious immunomodulatory molecule capable of inducing complete tumor regression in a syngeneic model of TCL exclusively in the presence of an intact immune system. These findings were confirmed in samples from our ongoing clinical study showing that tolinapant treatment can induce changes in gene expression and cytokine profile consistent with immune modulation. Mechanistically, we show that tolinapant can activate both the adaptive and the innate arms of the immune system through the induction of immunogenic forms of cell death. In summary, we describe a novel role for IAP antagonists as immunomodulatory molecules capable of promoting a robust antitumor immune response in TCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003955","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T22:58:02Z","timestamp":1630623482000},"page":"4003-4016","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7925-8335","authenticated-orcid":false,"given":"Nicola","family":"Ferrari","sequence":"first","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9960-3896","authenticated-orcid":false,"given":"George","family":"Ward","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gewinner","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-3651","authenticated-orcid":false,"given":"Matthew P.","family":"Davis","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Jueliger","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Saini","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Munck","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Smyth","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ferraldeschi","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Keer","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Inc., Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lyons","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Sims","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Cambridge, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"issue":"20","key":"2022040817590578900_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"10","key":"2022040817590578900_B2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood."},{"issue":"23","key":"2022040817590578900_B3","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1158\/1078-0432.CCR-09-1995","article-title":"New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies","volume":"16","author":"Dunleavy","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2022040817590578900_B4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: from the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"2022040817590578900_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a008730","article-title":"Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation","volume":"5","author":"Silke","year":"2013","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"2022040817590578900_B6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/B978-0-12-801430-1.00002-0","article-title":"IAP family of cell death and signaling regulators","volume":"545","author":"Silke","year":"2014","journal-title":"Methods Enzymol."},{"issue":"2","key":"2022040817590578900_B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer [published correction appears in Nat Rev Drug Discov. 2012;11(4):331]","volume":"11","author":"Fulda","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"2022040817590578900_B8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semcdb.2015.01.006","article-title":"Targeting extrinsic apoptosis in cancer: challenges and opportunities","volume":"39","author":"Fulda","year":"2015","journal-title":"Semin Cell Dev Biol."},{"issue":"9","key":"2022040817590578900_B9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/imt-2017-0185","article-title":"Regulation of innate and adaptive antitumor immunity by IAP antagonists","volume":"10","author":"Dougan","year":"2018","journal-title":"Immunotherapy."},{"issue":"2","key":"2022040817590578900_B10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molcel.2019.09.006","article-title":"The diversification of cell death and immunity: memento mori","volume":"76","author":"Legrand","year":"2019","journal-title":"Mol Cell."},{"issue":"16","key":"2022040817590578900_B11","doi-asserted-by":"crossref","first-page":"7314","DOI":"10.1021\/acs.jmedchem.8b00900","article-title":"A fragment-derived clinical candidate for antagonism of X-linked and cellular inhibitor of apoptosis proteins: 1-(6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)","volume":"61","author":"Johnson","year":"2018","journal-title":"J Med Chem."},{"issue":"7","key":"2022040817590578900_B12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-17-0848","article-title":"ASTX660, a novel non-peptidomimetic antagonist of cIAP1\/2 and XIAP, potently induces TNF\u03b1-dependent apoptosis in cancer cell lines and inhibits tumor growth","volume":"17","author":"Ward","year":"2018","journal-title":"Mol Cancer Ther."},{"key":"2022040817590578900_B13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/hon.211_2631","article-title":"Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1\/2 and XIAP antagonist, in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T cell lymphoma [abstract A072]","volume":"37","author":"Samaniego","year":"2019","journal-title":"Hematol Oncol."},{"issue":"12","key":"2022040817590578900_B14","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-19-1430","article-title":"A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma","volume":"26","author":"Mita","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2022040817590578900_B15","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br J Cancer."},{"issue":"8497","key":"2022040817590578900_B16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(86)92571-7","article-title":"The Animals (scientific procedures) Act 1986","volume":"2","author":"Hollands","year":"1986","journal-title":"Lancet."},{"issue":"10","key":"2022040817590578900_B17","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1084\/jem.20101123","article-title":"IAP inhibitors enhance co-stimulation to promote tumor immunity","volume":"207","author":"Dougan","year":"2010","journal-title":"J Exp Med."},{"issue":"2","key":"2022040817590578900_B18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nbt.2806","article-title":"Smac mimetics and innate immune stimuli synergize to promote tumor death","volume":"32","author":"Beug","year":"2014","journal-title":"Nat Biotechnol."},{"issue":"10","key":"2022040817590578900_B19","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/cdd.2017.94","article-title":"PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF","volume":"24","author":"Kearney","year":"2017","journal-title":"Cell Death Differ."},{"issue":"1","key":"2022040817590578900_B20","doi-asserted-by":"crossref","first-page":"E207","DOI":"10.3390\/cells9010207","article-title":"The immuno-modulatory effects of inhibitor of apoptosis protein antagonists in cancer immunotherapy","volume":"9","author":"Michie","year":"2020","journal-title":"Cells."},{"issue":"9","key":"2022040817590578900_B21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood."},{"issue":"2","key":"2022040817590578900_B22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/2326-6066.CIR-18-0428","article-title":"Antagonism of IAPs enhances CAR T-cell efficacy","volume":"7","author":"Michie","year":"2019","journal-title":"Cancer Immunol Res."},{"issue":"12","key":"2022040817590578900_B23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med."},{"key":"2022040817590578900_B24","first-page":"339ra370","article-title":"Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL","volume-title":"Sci Transl Med.","author":"McComb","year":"2016"},{"issue":"339","key":"2022040817590578900_B25","doi-asserted-by":"crossref","first-page":"339ra69","DOI":"10.1126\/scitranslmed.aad3099","article-title":"The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia","volume":"8","author":"Brumatti","year":"2016","journal-title":"Sci Transl Med."},{"issue":"8","key":"2022040817590578900_B26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrc2889","article-title":"IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer [published correction appears in Nat Rev Cancer. 2010;10:890]","volume":"10","author":"Gyrd-Hansen","year":"2010","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"2022040817590578900_B27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nri.2017.9","article-title":"Dying cells actively regulate adaptive immune responses","volume":"17","author":"Yatim","year":"2017","journal-title":"Nat Rev Immunol."},{"issue":"1-2","key":"2022040817590578900_B28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbagrm.2009.11.014","article-title":"High-mobility group box 1 and cancer","volume":"1799","author":"Tang","year":"2010","journal-title":"Biochim Biophys Acta."},{"issue":"9","key":"2022040817590578900_B29","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/cam4.827","article-title":"Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy","volume":"5","author":"Exner","year":"2016","journal-title":"Cancer Med."},{"issue":"2","key":"2022040817590578900_B30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.celrep.2016.03.037","article-title":"Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity","volume":"15","author":"Aaes","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"2022040817590578900_B31","doi-asserted-by":"crossref","first-page":"1710398","DOI":"10.1080\/2162402X.2019.1710398","article-title":"ASTX660, an antagonist of cIAP1\/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer","volume":"9","author":"Ye","year":"2020","journal-title":"OncoImmunology."},{"issue":"1","key":"2022040817590578900_B32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kepp","year":"2011","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"2022040817590578900_B33","doi-asserted-by":"crossref","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"OncoImmunology."},{"issue":"19","key":"2022040817590578900_B34","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1182\/bloodadvances.2019000796","article-title":"TNFR2 is required for RIP1-dependent cell death in human leukemia","volume":"4","author":"Aguad\u00e9-Gorgori\u00f3","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022040817590578900_B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity."},{"issue":"7637","key":"2022040817590578900_B36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature."},{"issue":"6286","key":"2022040817590578900_B37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"Cancer immunology. The \u201ccancer immunogram.\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science."},{"issue":"1","key":"2022040817590578900_B38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity."},{"key":"2022040817590578900_B39","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminhematol.2010.01.014","article-title":"Novel agents in development for peripheral T-cell lymphoma","volume":"47","author":"O\u2019Connor","year":"2010","journal-title":"Semin Hematol."},{"issue":"9","key":"2022040817590578900_B40","doi-asserted-by":"crossref","first-page":"e1471440","DOI":"10.1080\/2162402X.2018.1471440","article-title":"Antagonist of cIAP1\/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer","volume":"7","author":"Xiao","year":"2018","journal-title":"OncoImmunology."},{"issue":"3","key":"2022040817590578900_B41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","article-title":"Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold [published correction appears in Cell. 2020;180(2):404\u2013405]","volume":"178","author":"Vredevoogd","year":"2019","journal-title":"Cell."},{"issue":"3","key":"2022040817590578900_B42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov."},{"key":"2022040817590578900_B43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-981-15-3266-5_4","article-title":"Discovery of new immune checkpoints: family grows up","volume":"1248","author":"Kong","year":"2020","journal-title":"Adv Exp Med Biol."},{"issue":"1","key":"2022040817590578900_B44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/imr.12583","article-title":"Necroptotic cell death in anti-cancer therapy","volume":"280","author":"Krysko","year":"2017","journal-title":"Immunol Rev."},{"issue":"5","key":"2022040817590578900_B45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","article-title":"The molecular machinery of regulated cell death","volume":"29","author":"Tang","year":"2019","journal-title":"Cell Res."},{"issue":"2","key":"2022040817590578900_B46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","article-title":"Necroptosis: the release of damage-associated molecular patterns and its physiological relevance","volume":"38","author":"Kaczmarek","year":"2013","journal-title":"Immunity."},{"issue":"6258","key":"2022040817590578900_B47","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.aad0395","article-title":"RIPK1 and NF-\u03baB signaling in dying cells determines cross-priming of CD8+ T cells","volume":"350","author":"Yatim","year":"2015","journal-title":"Science."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2022007185","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4003\/1888089\/advancesadv2020003955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4003\/1888089\/advancesadv2020003955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T17:59:35Z","timestamp":1649440775000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/20\/4003\/476765\/Antagonism-of-inhibitors-of-apoptosis-proteins"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":47,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003955","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2022007185","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]}}}